Prothena Corp Public Ltd Co
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.10%
vs ±12.2% implied · ×0.17
shaded = implied · ▲▼ = realized
Prothena Corp Public has 9 disclosed suppliers and 3 disclosed customers in SEC filings.
Prothena Corp Public Ltd Co
8.47
SentenceWe are dependent on BMS, and its third-party manufacturers if applicable, to manufacture clinical supplies of BMS-986446.
PRTA 10-Kaccession 0001559053-26-000008
SentencePrasinezumab - Boehringer Ingelheim Biopharmaceuticals GmbH ("BI") manufactured clinical supplies of our drug candidate prasinezumab for our completed Phase 1a single ascending dose and Phase 1b multiple ascending dose clinical trials.
PRTA 10-Kaccession 0001559053-26-000008
SentenceBMS, with whom we are collaborating on development of BMS-986446, is responsible for manufacturing clinical supplies for any subsequent clinical trials for BMS-986446.
PRTA 10-Kaccession 0001559053-26-000008
SentenceBMS-986446 (formerly PRX005) - Catalent Pharma Solutions, LLC ("Catalent Pharma") was our third-party manufacturer for drug substance and Sharp Sterile Manufacturing, LLC (formerly known as "Berkshire Sterile Manufacturing, LLC" and hereinafter referred to as "Sharp Sterile") was our third-party manufacturer for drug product for our drug candidate BMS-986446 for our Phase 1 clinical trial.
PRTA 10-Kaccession 0001559053-26-000008
SentenceLonza Ltd ("Lonza") is our third-party manufacturer of clinical supplies of our drug candidate PRX019.
PRTA 10-Kaccession 0001559053-26-000008
SentenceWe are dependent on Novo Nordisk, and its third-party manufacturers if applicable, to manufacture clinical supplies of coramitug.
PRTA 10-Kaccession 0001559053-26-000008
SentenceCoramitug (formerly PRX004) - Rentschler Biopharma SE ("Rentschler") manufactured clinical supplies of our drug candidate coramitug for our completed Phase 1 clinical trial.
PRTA 10-Kaccession 0001559053-26-000008
SentenceUnder the terms of our collaboration with Roche, Roche is responsible for that further development, including the conduct of the Phase 3 clinical trial and any future clinical trial of that drug candidate.
PRTA 10-Kaccession 0001559053-26-000008
SentenceBMS-986446 (formerly PRX005) - Catalent Pharma Solutions, LLC ("Catalent Pharma") was our third-party manufacturer for drug substance and Sharp Sterile Manufacturing, LLC (formerly known as "Berkshire Sterile Manufacturing, LLC" and hereinafter referred to as "Sharp Sterile") was our third-party manufacturer for drug product for our drug candidate BMS-986446 for our Phase 1 clinical trial.
PRTA 10-Kaccession 0001559053-26-000008
In July 2021, we announced that we and Novo Nordisk entered into a definitive purchase agreement under which Novo Nordisk acquired our clinical stage antibody coramitug and broader ATTR amyloidosis business.
PRTA 10-Kaccession 0001559053-26-000008
SentencePursuant to the Collaboration Agreement with Roche, we are eligible to receive payments for commercial and regulatory milestones and royalties on net sales of Collaboration Products.
PRTA 10-Kaccession 0001559053-26-000008
Linked news
Expected move
Inputsspot 8.47exp Nov 20ATM strike 8ATM straddle 2.98IV 190%